ArriVent BioPharma, Inc. (AVBP) stock
AVBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.90+0.21 (+1.96%)
Close on Nov 18, 2026Market cap $537.45MP/E –Yield –
ArriVent BioPharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
ArriVent BioPharma's operating income for the twelve months ending Jun 30, 2026 was -$175.94M. For fiscal 2025 it was -$177.53M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$177.53M | – |
| FY2024 | Dec 31, 2024 | -$94.31M | – |
| FY2023 | Dec 31, 2023 | -$74.59M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$52.69M | – |
| Q1 FY2026 | Mar 31, 2026 | -$46.11M | – |
| Q4 FY2025 | Dec 31, 2025 | -$38.82M | – |
| Q3 FY2025 | Sep 30, 2025 | -$38.32M | – |
| Q2 FY2025 | Jun 30, 2025 | -$33.62M | – |
| Q1 FY2025 | Mar 31, 2025 | -$66.77M | – |
| Q4 FY2024 | Dec 31, 2024 | -$23.71M | – |
| Q3 FY2024 | Sep 30, 2024 | -$24.23M | – |
| Q2 FY2024 | Jun 30, 2024 | -$25.70M | – |
| Q1 FY2024 | Mar 31, 2024 | -$20.67M | – |
| Q4 FY2023 | Dec 31, 2023 | -$23.12M | – |
| Q3 FY2023 | Sep 30, 2023 | -$16.72M | – |
| Q2 FY2023 | Jun 30, 2023 | -$22.58M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.17M | – |
See a number that looks wrong?